| DB ID | MyCo_1094 |
| Title | Is (1→3)-β-D-glucan the missing link from bedside assessment to pre-emptive therapy of invasive candidiasis? |
| Year | 2011 |
| PMID | 22171793 |
| Fungal Diseases involved | Invasive candidiasis |
| Associated Medical Condition | None |
| Genus | Candida |
| Species | spp. |
| Organism | Candida spp. |
| Ethical Statement | None |
| Site of Infection | None |
| Opportunistic invasive | Invasive |
| Sample type | None |
| Sample source | None |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | BDG |
| Biomarker Full Name | 1-3-beta-D-Glucan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Switzerland |
| Cohort | None |
| Cohort No. | None |
| Age Group | None |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | None |
| Technique | Assay |
| Analysis Method | BDG assay |
| ELISA kits | None |
| Assay Data | None |
| Validation Techniques used | BDG Assay |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
